This PDF file includes:
Fig. S1. Muscle-specific transgenic overexpression of ML1. Fig. S2 . Muscle-specific transgenic overexpression of ML1 reduces GAS, DIA, and cardiac pathologies in mdx mice. Cre (ML1   MCK   ) , mdx, and mdx; ML1 MCK mice. Note that the tissue-specific proteolytic cleavage products of full-length GCaMP3-ML1 were also recognized by an anti-GFP antibody, which can be used to detect GCaMP proteins (15). (C) Western blotting analysis of GCaMP3-ML1 expression in ML1 MCK DIA and cardiac muscle with anti-GFP antibody. (D, E) Quantification of lysosomal Ca 2+ release from ML1 MCK and mdx;ML1 MCK myotubes (see Fig. 1H, I ). All data are means ± s.e.m.; **p < 0.01; ****p < 0.0001. Only male mdx mice were used for echocardiography, but both male and female mice were included in the histology analysis. Scale = 500 m (low magnification) or 50 m (high magnification). All data are means ± s.e.m.; *p < 0.05, **p < 0.01. (J, K) EB dye uptake in TA from ML-SI6-injected mdx mice. Scale = 100 m. Male and female mice were randomly assigned to different treatment groups in experiments shown in this figure. All data are mean ± s.e.m.; *p < 0.05, and **p < 0.01.
Fig. S5. Activation of ML1 corrects lysosomal insufficiency and improves sarcolemmal repair in mdx mice. (A, B)
Transgenic overexpression of ML1 decreased EB dye uptake in DIA from mdx mice at the age of 1 mo.. Scale = 100 m. (C, D) ML-SA5 (2, 5 mg/kg) treatment decreased EBpositive fibers before and after treadmill exercise. Scale = 10 m. (E) Lamp1 expression was high in CD11b-positive macrophages. Scale bar = 100 m. (F, G) TFEB immunolabeling in GAS from WT, ML1 MCK , mdx, and mdx;ML1 MCK mice. Scale bar = 10 m. Each datum represents one muscle fiber in randomly selected images from at least four animals in each group. (H) Treatment of 2 mg/kg ML-SA5 for 14 d decreased TFEB intensity (see Fig. 6G ). (I) Western blotting analysis of LC3-II expression levels in GAS from various transgenic mice. Both male and female mice were used. All data are means ± s.e.m.; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. (F) and quantification (G) for TFE3 immunolabeling of WT and DMD myoblasts upon ML-SA5 (0.5 M) and ML-SI3 (20 M) treatment. Scale = 10 m. (H) mRNA expression levels of TFEB target genes determined by qPCR. HPRT was used as a control. (I-K) Lamp1 and TFEB protein levels in WT and DMD myoblasts were increased and decreased, respectively, upon ML-SA5 (0.5 M) treatment for 12 h and 24 h. All data are means ± s.e.m.; *p < 0.05, **p < 0.01, and ****p < 0.0001. (A, B) The effects of ML-SA5 washout on TFEB nuclear translocation. Scale = 10 m. (C) H&E staining of TA muscle sections from mdx mice that were treated with ML-SA5 at P14 for one week followed by drug withdrawal for another week. Mice were sacrificed at the age of 1 mo.. (D, E) Quantifications of necrotic area (D) and central-nucleation (E) in the muscle sections shown in C. All data are means ± s.e.m.; ****p < 0.0001.
